These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36761735)

  • 1. A novel defined TLR3 agonist as an effective vaccine adjuvant.
    Ko KH; Cha SB; Lee SH; Bae HS; Ham CS; Lee MG; Kim DH; Han SH
    Front Immunol; 2023; 14():1075291. PubMed ID: 36761735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
    Hafner AM; Corthésy B; Merkle HP
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.
    Lebedeva E; Bagaev A; Pichugin A; Chulkina M; Lysenko A; Tutykhina I; Shmarov M; Logunov D; Naroditsky B; Ataullakhanov R
    BMC Immunol; 2018 Jul; 19(1):26. PubMed ID: 30055563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aqueous extracts from cultivated Cistanche deserticola Y.C. Ma as polysaccharide adjuvant promote immune responses via facilitating dendritic cell activation.
    Feng S; Yang X; Weng X; Wang B; Zhang A
    J Ethnopharmacol; 2021 Sep; 277():114256. PubMed ID: 34062250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection.
    Jelinek I; Leonard JN; Price GE; Brown KN; Meyer-Manlapat A; Goldsmith PK; Wang Y; Venzon D; Epstein SL; Segal DM
    J Immunol; 2011 Feb; 186(4):2422-9. PubMed ID: 21242525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.
    Sugiyama T; Hoshino K; Saito M; Yano T; Sasaki I; Yamazaki C; Akira S; Kaisho T
    Int Immunol; 2008 Jan; 20(1):1-9. PubMed ID: 17981792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV.
    Poteet E; Lewis P; Chen C; Ho SO; Do T; Chiang S; Labranche C; Montefiori D; Fujii G; Yao Q
    Vaccine; 2016 Nov; 34(48):5886-5894. PubMed ID: 27997339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-stimulation with TLR3 and TLR21 ligands synergistically up-regulates Th1-cytokine IFN-γ and regulatory cytokine IL-10 expression in chicken monocytes.
    He H; Genovese KJ; Swaggerty CL; MacKinnon KM; Kogut MH
    Dev Comp Immunol; 2012 Apr; 36(4):756-60. PubMed ID: 22120532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation.
    Ohmura M; Yamamoto M; Tomiyama-Miyaji C; Yuki Y; Takeda Y; Kiyono H
    Infect Immun; 2005 Jul; 73(7):4088-97. PubMed ID: 15972497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct effect of dsRNA mimetics on cancer cells induces endogenous IFN-β production capable of improving dendritic cell function.
    Gatti G; Nuñez NG; Nocera DA; Dejager L; Libert C; Giraudo C; Maccioni M
    Eur J Immunol; 2013 Jul; 43(7):1849-61. PubMed ID: 23636788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CCR4 antagonist enhances DC activation and homing to the regional lymph node and shows potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment.
    Yamamoto S; Matsuo K; Nagakubo D; Higashiyama S; Nishiwaki K; Oiso N; Kawada A; Yoshie O; Nakayama T
    J Pharmacol Sci; 2018 Mar; 136(3):165-171. PubMed ID: 29519579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta.
    Ngoi SM; Tovey MG; Vella AT
    J Immunol; 2008 Dec; 181(11):7670-80. PubMed ID: 19017955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
    Seya T; Shime H; Takeda Y; Tatematsu M; Takashima K; Matsumoto M
    Cancer Sci; 2015 Dec; 106(12):1659-68. PubMed ID: 26395101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.
    Salem ML; Kadima AN; Cole DJ; Gillanders WE
    J Immunother; 2005; 28(3):220-8. PubMed ID: 15838378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysaccharides from Ganoderma formosanum function as a Th1 adjuvant and stimulate cytotoxic T cell response in vivo.
    Pi CC; Chu CL; Lu CY; Zhuang YJ; Wang CL; Yu YH; Wang HY; Lin CC; Chen CJ
    Vaccine; 2014 Jan; 32(3):401-8. PubMed ID: 24252697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-stranded RNA exacerbates pulmonary allergic reaction through TLR3: implication of airway epithelium and dendritic cells.
    Torres D; Dieudonné A; Ryffel B; Vilain E; Si-Tahar M; Pichavant M; Lassalle P; Trottein F; Gosset P
    J Immunol; 2010 Jul; 185(1):451-9. PubMed ID: 20505141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells.
    Wang C; Zhuang Y; Zhang Y; Luo Z; Gao N; Li P; Pan H; Cai L; Ma Y
    Vaccine; 2012 Jul; 30(32):4790-9. PubMed ID: 22634298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.